Page 1851 - Williams Hematology ( PDFDrive )

1826 Part XII: Hemostasis and Thrombosis Chapter 111: Megakaryopoiesis and Thrombopoiesis 1827

37. Hodohara K, Fujii N, Yamamoto N, Kaushansky K: Stromal cell-derived factor-1 (SDF- 70. Eckly A, Strassel C, Freund M, et al: Abnormal megakaryocyte morphology and
1) acts together with thrombopoietin to enhance the development of megakaryocytic proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
progenitor cells (CFU-MK). Blood 95:769, 2000. Blood 113(14):3182, 2009.
38. Avecilla ST, Hattori K, Heissig B, et al: Chemokine-mediated interaction of hematopoi- 71. De Botton S, Sabri S, Daugas E, et al: Platelet formation is the consequence of caspase
etic progenitors with the bone marrow vascular niche is required for thrombopoiesis. activation within megakaryocytes. Blood 100:1310, 2002.
Nat Med 10:64, 2004. 72. Quesenberry PJ, Ihle JN, McGrath E: The effect of interleukin 3 and GM-CSA-2 on
39. Geddis AE, Fox NE, Kaushansky K: Phosphatidylinositol 3-kinase is necessary but not megakaryocyte and myeloid clonal colony formation. Blood 65:214, 1985.
sufficient for thrombopoietin-induced proliferation in engineered Mp1-bearing cell 73. Kaushansky K, O’Hara PJ, Berkner K, et al: Genomic cloning, characterization, and
lines as well as in primary megakaryocytic progenitors. J Biol Chem 276:34473, 2001. multilineage growth-promoting activity of human granulocyte-macrophage colony-
40. Miyazaki R, Ogata H, Kobayashi Y: Requirement of thrombopoietin-induced activation stimulating factor. Proc Natl Acad Sci U S A 83:3101, 1986.
of ERK for megakaryocyte differentiation and of p38 for erythroid differentiation. Ann 74. Briddell RA, Bruno E, Cooper RJ, et al: Effect of c-kit ligand on in vitro human
Hematol 80:284, 2001. megakaryocytopoiesis. Blood 78:2854, 1991.
41. Pettiford SM, Herbst R: The protein tyrosine phosphatase HePTP regulates nuclear 75. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood
translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells. 86:419, 1995.
Leukemia 17:366, 2003. 76. Yang YC, Ciarletta AB, Temple PA, et al: Human IL-3 (multi-CSF): Identification by
42. Dorsey JF, Cunnick JM, Mane SM, Wu J: Regulation of the Erk2-Elk1 signaling pathway expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell
and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. Blood 47:3, 1986.
99:1388, 2002. 77. Wong GG, Witek JS, Temple PA, et al: Human GM-CSF: Molecular cloning of the com-
43. Zhang Y, Nagata Y, Yu G, et al: Aberrant quantity and localization of Aurora-B/AIM-1 plementary DNA and purification of the natural and recombinant proteins. Science
and survivin during megakaryocyte polyploidization and the consequences of Auro- 228:810, 1985.
ra-B/AIM-1-deregulated expression. Blood 103:3717, 2004. 78. Feng Y, Klein BK, Vu L, et al: 1H 13C, and 15N NMR resonance assignments, secondary
44. Carow CE, Fox NE, Kaushansky K: Kinetics of endomitosis in primary murine structure, and backbone topology of a variant of human interleukin-3. Biochemistry
megakaryocytes. J Cell Physiol 188:291, 2001. 34:6540, 1995.
45. Geddis AE, Kaushansky K: Megakaryocytes express functional aurora kinase B in 79. Lopez AF, Eglinton JM, Gillis D, et al: Reciprocal inhibition of binding between inter-
endomitosis. Blood 104:1017, 2004. leukin 3 and granulocyte-macrophage colony-stimulating factor to human eosinophils.
46. Geddis AE, Fox NE, Tkachenko E, Kaushansky K: Endomitotic megakaryocytes that Proc Natl Acad Sci U S A 86:7022, 1989.
form a bipolar spindle exhibit cleavage furrow ingression followed by furrow regres- 80. Scott CL, Robb L, Mansfield R, et al: Granulocyte-macrophage colony-stimulating
sion. Cell Cycle 6:455, 2007. factor is not responsible for residual thrombopoiesis in Mpl null mice. Exp Hematol
47. Suzuki A, Shin JW, Wang Y, et al: RhoA is essential for maintaining normal megakary- 28:1001, 2000.
ocyte ploidy and platelet generation. PLoS One 8:e69315, 2013. 81. Chen Q, Solar G, Eaton DL, de Sauvage FJ: IL-3 does not contribute to platelet produc-
48. Gao Y, Smith E, Ker E, et al: Role of RhoA-specific guanine exchange factors in regula- tion in c-Mpl–deficient mice. Stem Cells 16(Suppl 2):31, 1998.
tion of endomitosis in megakaryocytes. Dev Cell 22:573, 2012. 82. Kishimoto T: The biology of interleukin-6. Blood 74:1, 1989.
49. Seri M, Cusano R, Gangarossa S, et al: Mutations in MYH9 result in the May-Hegglin 83. Quesenberry PJ, McGrath HE, Williams ME, et al: Multifactor stimulation of megakary-
anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syn- ocytopoiesis: Effects of interleukin 6. Exp Hematol 19:35, 1991.
drome Consortium. Nat Genet 26:103, 2000. 84. Williams N, De Giorgio T, Banu N, et al: Recombinant interleukin 6 stimulates imma-
50. Hartwig J, Italiano J Jr: The birth of the platelet. J Thromb Haemost 1:1580, 2003. ture murine megakaryocytes. Exp Hematol 18:69, 1990.
51. Visvader JE, Elefanty AG, Strasser A, Adams JM: GATA-1 but not SCL induces 85. Mei RL, Burstein SA: Megakaryocytic maturation in murine long-term bone marrow
megakaryocytic differentiation in an early myeloid line. EMBO J 11:4557, 1992. culture: Role of interleukin-6. Blood 78:1438, 1991.
52. Huizing M, Parkes JM, Helip-Wooley A, White JG, Gahl WA: Platelet alpha granules 86. Ishibashi T, Kimura H, Shikama Y, et al: Interleukin-6 is a potent thrombopoietic factor
in BLOC-2 and BLOC-3 subtypes of Hermansky-Pudlak syndrome. Platelets 18:150, in vivo in mice. Blood 74:1241, 1989.
2007. 87. Asano S, Okano A, Ozawa K, et al: In vivo effects of recombinant human interleukin-6
53. Tavassoli M, Aoki M: Localization of megakaryocytes in the bone marrow. Blood Cells in primates: Stimulated production of platelets. Blood 75:1602, 1990.
15:3, 1989. 88. van Gameren MM, Willemse PH, Mulder NH, et al: Effects of recombinant human
54. Andrews NC, Erdjument-Bromage H, Davidson MB, et al: Erythroid transcription fac- interleukin-6 in cancer patients: A phase I–II study. Blood 84:1434, 1994.
tor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature 362:722, 89. Blay JY, Favrot M, Rossi JF, Wijdenes J: Role of interleukin-6 in paraneoplastic throm-
1993. bocytosis. Blood 82:2261, 1993.
55. Bean TL, Ney PA: Multiple regions of p45 NF-E2 are required for beta-globin gene 90. Bernad A, Kopf M, Kulbacki R, et al: Interleukin-6 is required in vivo for the regulation
expression in erythroid cells. Nucleic Acids Res 25:2509, 1997. of stem cells and committed progenitors of the hematopoietic system. Immunity 1:725,
56. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al: Transcription factor NF-E2 is 1994.
required for platelet formation independent of the actions of thrombopoietin/MGDF 91. Kaser A, Brandacher G, Steurer W, et al: Interleukin-6 stimulates thrombopoiesis
in megakaryocyte development. Cell 81:695, 1995. through thrombopoietin: Role in inflammatory thrombocytosis. Blood 98:2720, 2001.
57. Querfurth E, Schuster M, Kulessa H, et al: Antagonism between C/EBPbeta and FOG 92. Du X, Williams DA: Interleukin-11: Review of molecular, cell biology, and clinical use.
in eosinophil lineage commitment of multipotent hematopoietic progenitors. Genes Blood 89:3897, 1997.
Dev 14:2515, 2000. 93. Gough NM: Molecular genetics of leukemia inhibitory factor (LIF) and its receptor.
58. Tijssen MR, Ghevaert C. Transcription factors in late megakaryopoiesis and related Growth Factors 7:175, 1992.
platelet disorders. J Thromb Haemost 11:593, 2013. 94. Hilton DJ: LIF: Lots of interesting functions. Trends Biochem Sci 17:72, 1992.
59. Howell WH DD: The production of blood platelets in the lungs. J Exp Med 65:177, 1939. 95. Debili N, Masse JM, Katz A, et al: Effects of the recombinant hematopoietic growth
60. Slater DN, Trowbridge EA, Martin JF: The megakaryocyte in thrombocytopenia: A factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on
microscopic study which supports the theory that platelets are produced in the pulmo- the megakaryocytic differentiation of CD34+ cells. Blood 82:84, 1993.
nary circulation. Thromb Res 31:163, 1983. 96. Teramura M, Kobayashi S, Hoshino S, et al: Interleukin-11 enhances human megakary-
61. Kaushansky K, Lok S, Holly RD, et al: Promotion of megakaryocyte progenitor expan- ocytopoiesis in vitro. Blood 79:327, 1992.
sion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568, 1994. 97. Metcalf D, Nicola NA, Gearing DP: Effects of injected leukemia inhibitory factor on
62. Kaufman RM, Airo R, Pollack S, et al: Origin of pulmonary megakaryocytes. Blood hematopoietic and other tissues in mice. Blood 76:50, 1990.
25:767, 1965. 98. Neben TY, Loebelenz J, Hayes L, et al: Recombinant human interleukin-11 stimulates
63. Harker LA, Marzec UM, Kelly AB: Effects of Mpl ligands on platelet production and megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized
function in nonhuman primates. Stem Cells 16(Suppl 2):107, 1998. mice. Blood 81:901, 1993.
64. Choi ES, Nichol JL, Hokom MM, et al: Platelets generated in vitro from proplatelet-dis- 99. Farese AM, Myers LA, MacVittie TJ: Therapeutic efficacy of recombinant human leu-
playing human megakaryocytes are functional. Blood 85:402, 1995. kemia inhibitory factor in a primate model of radiation-induced marrow aplasia. Blood
65. Norol F, Vitrat N, Cramer E, et al: Effects of cytokines on platelet production from 84:3675, 1994.
blood and marrow CD34+ cells. Blood 91:830, 1998. 100. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al: A phase I trial of recombinant
66. Rojnuckarin P, Kaushansky K: Actin reorganization and proplatelet formation in human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer
murine megakaryocytes: The role of protein kinase C alpha. Blood 97:154, 2001. receiving chemotherapy. Blood 87:3615, 1996.
67. Ishida Y, Yano K, Ito T, et al: Purification of proplatelet formation (PPF) stimulating 101. Nandurkar HH, Robb L, Tarlinton D, et al: Adult mice with targeted mutation of the
factor: Thrombin/antithrombin III complex stimulates PPF of megakaryocytes in vitro interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 90:2148, 1997.
and platelet production in vivo. Thromb Haemost 85:349, 2001. 102. Gainsford T, Nandurkar H, Metcalf D, et al: The residual megakaryocyte and platelet
68. Hunt P, Hokom MM, Wiemann B, et al: Megakaryocyte proplatelet-like process forma- production in c-Mpl–deficient mice is not dependent on the actions of interleukin-6,
tion in vitro is inhibited by serum prothrombin, a process which is blocked by matrix interleukin-11, or leukemia inhibitory factor. Blood 95:528, 2000.
-bound glycosaminoglycans. Exp Hematol 21:372, 1993. 103. Lyman SD, James L, Vanden Bos T, et al: Molecular cloning of a ligand for the flt3/flk-2
69. Geddis AE, Kaushansky K: Inherited thrombocytopenias: Toward a molecular under- tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell
standing of disorders of platelet production. Curr Opin Pediatr 16:15, 2004. 75:1157, 1993.

Kaushansky_chapter 111_p1813-1828.indd 1826 9/21/15 4:11 PM